文献速递眼底病与葡萄膜炎

雷珠单抗联合或不联合激光治疗视网膜分支静脉阻塞的持续获益:BRIGHTER研究24个月结果

Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
PubMed 文献 · Ophthalmology · 2017-08-12

BRIGHTER研究为IIIb期开放标签随机对照多中心研究,纳入455例视网膜分支静脉阻塞继发黄斑水肿患者,随机接受雷珠单抗0.5 mg、雷珠单抗联合激光或激光治疗。24个月结果显示,雷珠单抗联合或不联合激光的BCVA获益优于激光组,联合激光不减少注射次数。

要点

  • 雷珠单抗联合或不联合激光的BCVA获益优于激光组(17.3/15.5 vs 11.6字母,P<0.0001)。
  • 雷珠单抗联合激光非劣于雷珠单抗单药(平均平均BCVA变化15.4 vs 15.0字母,P<0.0001)。
  • 联合激光未减少雷珠单抗注射次数(平均11.4 vs 11.3次,P=0.4259)。

核心结论

  • BRIGHTER研究结果证实,以个体化视力稳定标准驱动的雷珠单抗0.5 mg按需给药在视网膜分支静脉阻塞患者中具有长期疗效和安全性。
  • 联合激光未带来更好的功能结局或更低的治疗需求。
  • 安全性结果与雷珠单抗已确立的安全性特征一致。

研究设计与样本

  • IIIb期、开放标签、随机、活性对照、三臂、多中心研究,共纳入455例患者。
  • 患者按2:2:1随机分为雷珠单抗0.5 mg组(n=183)、雷珠单抗0.5 mg联合激光组(n=180)或激光组(第6个月后可选择雷珠单抗0.5 mg;n=92)。
  • 雷珠单抗联合或不联合激光组在初始3次每月注射后,接受以视力稳定标准驱动的按需治疗;激光组由研究者酌情给予激光。

主要发现

  • 共380例患者(83.5%)完成研究。
  • 雷珠单抗联合或不联合激光的BCVA结局优于激光组(单药及第6个月起联合雷珠单抗;17.3/15.5 vs 11.6字母;P<0.0001)。
  • 雷珠单抗联合激光非劣于雷珠单抗单药(平均平均BCVA变化:15.4 vs 15.0字母;P<0.0001)。
  • 联合激光未减少雷珠单抗注射次数(平均注射次数:11.4 vs 11.3;P=0.4259)。
  • 24个月内,雷珠单抗联合或不联合激光较激光单药治疗显示更大的CSFT降低(雷珠单抗单药-224.7 μm,雷珠单抗联合激光-248.9 μm,激光[单药及第6个月起联合雷珠单抗]-197.5 μm)。

关键数值与推荐

  • 主要结局指标为基线至第24个月最佳矫正视力(BCVA)和中心视网膜亚区厚度(CSFT)的平均变化(及平均平均变化)以及24个月安全性。
  • 雷珠单抗联合或不联合激光的BCVA获益优于激光组(17.3/15.5 vs 11.6字母;P<0.0001)。
  • 雷珠单抗联合激光非劣于雷珠单抗单药(平均平均BCVA变化:15.4 vs 15.0字母;P<0.0001)。
  • 联合激光未减少雷珠单抗注射次数(平均注射次数:11.4 vs 11.3;P=0.4259)。
  • 24个月内CSFT降低:雷珠单抗单药-224.7 μm,雷珠单抗联合激光-248.9 μm,激光组-197.5 μm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the long-term (24-month) efficacy and safety of ranibizumab 0.5 mg administered pro re nata (PRN) with or without laser using an individualized visual acuity (VA) stabilization criteria in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). DESIGN: Phase IIIb, open-label, randomized, active-controlled, 3-arm, multicenter study. PARTICIPANTS: A total of 455 patients. METHODS: Patients were randomized (2:2:1) to ranibizumab 0.5 mg (n = 183), ranibizumab 0.5 mg with laser (n = 180), or laser (with optional ranibizumab 0.5 mg after month 6; n = 92). After initial 3 monthly injections, patients in the ranibizumab with or without laser arms received VA stabilization criteria-driven PRN treatment. Patients assigned to the laser arm received laser at the investigator's discretion. MAIN OUTCOME MEASURES: Mean (and mean average) change in best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) from baseline to month 24, and safety over 24 months. RESULTS: A total of 380 patients (83.5%) completed the study. Ranibizumab with or without laser led to superior BCVA outcomes versus laser (monotherapy and combined with ranibizumab from month 6; 17.3/15.5 vs. 11.6 letters; P < 0.0001). Ranibizumab with laser was noninferior to ranibizumab monotherapy (mean average BCVA change: 15.4 vs. 15.0 letters; P < 0.0001). However, addition of laser did not reduce the number of ranibizumab injections (mean injections: 11.4 vs. 11.3; P = 0.4259). A greater reduction in CSFT was seen with ranibizumab with or without laser versus laser monotherapy over 24 months from baseline (ranibizumab monotherapy -224.7 μm, ranibizumab with laser -248.9 μm, laser [monotherapy and combined with ranibizumab from month 6] -197.5 μm). Presence of macular ischemia did not affect BCVA outcome or treatment frequency. There were no reports of neovascular glaucoma or iris neovascularization. No new safety signals were identified. CONCLUSIONS: The BRIGHTER study results confirmed the long-term efficacy and safety profile of PRN dosing driven by individualized VA stabilization criteria using ranibizumab 0.5 mg in patients with BRVO. Addition of laser did not lead to better functional outcomes or lower treatment need. The safety results were consistent with the well-established safety profile of ranibizumab.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Tadayoni R, Waldstein SM, Boscia F, et al. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology. 2017. PMID: 28807635. doi:10.1016/j.ophtha.2017.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。